Anupam M. Desai

Oncology · 2016

A researcher in the Science corpus: 1 paper; trusts 5 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom Anupam M. Desai trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Lieping Chen
  2. C. Robert

Papers from Anupam M. Desai's perspective

Ordered by how strongly the researchers Anupam M. Desai trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
  2. The blockade of immune checkpoints in cancer immunotherapy (Nature Reviews. Cancer)
  3. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
  4. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. (Immunity)
  5. Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma (New England Journal of Medicine)
  6. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients (Nature)
  7. The B7 family revisited. (Annual Review of Immunology)
  8. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells (Journal of Experimental Medicine)
  9. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer (Nature)
  10. Pembrolizumab for the treatment of non-small-cell lung cancer. (New England Journal of Medicine)

Their papers